Drug intelligence / Profile preview

Novanight

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Novanight is a multi-ingredient dietary supplement formulated to improve sleep quality and reduce the time required to fall asleep. Originally developed by Sanofi and currently marketed by Opella Healthcare, the product features a "Triple Action" formulation. Its primary active components include melatonin (1 mg), which acts as an agonist at melatonin receptors to regulate the circadian rhythm, and a blend of botanical extracts: passionflower (Passiflora incarnata), California poppy (Eschscholtzia californica), and lemon balm (Melissa officinalis). The formulation is often supplemented with vitamin B6 to support normal psychological function. Novanight is available in oral formats such as tablets and sachets and is positioned within the consumer healthcare market for adults experiencing transient sleep disturbances.

Brand names
NovanightNovanight Triple Action
Other names
Novanuit good night triple actionNovanuit Sommeil Triple Action
02

Targets

MTNR1B (Melatonin Receptor 2)MTNR1A (MT1)

Beyond the preview

Go deeper on Novanight.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novanight.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call